Wednesday 31 July 2013
ON01910 / Estybon / Rigosertib
The dual pathway inhibitor rigosertib inhibits phosphoinositide 3-kinase (PI3K) pathway (PI3K pathway) activation as well as polo-like kinase 1 (PLK1) activity across a broad spectrum of cancer cell lines.
ON01910/Estybon/Rigosertib is in 2012 in Phase III clinical trials and shows promise as a powerful anti-cancer agent, especially for the treatment of myelodysplastic syndrome (MDS) and pancreatic cancer.
The dual pathway inhibitor rigosertib is effective in direct-patient tumor xenografts of head and neck squamous cell carcinomas. Anderson RT, Keysar SB, Bowles DW, Glogowska MJ, Astling DP, Morton JJ, Le P, Umpierrez A, Eagles-Soukup J, Gan GN, Vogler BW, Sehrt DB, Takimoto SM, Aisner DL, Wilhem F, Frederick BA, Varella-Garcia M, Tan AC, Jimeno A. Mol Cancer Ther. 2013 Jul 23. PMID: 23873848